Ryan J. Sullivan, MD

Massachusetts General Hospital

Academic Titles

Associate Professor, Medicine, Harvard Medical School

Research Program Affiliation

Member, Cancer Immunology

Member, Head and Neck Cancer

Member, Melanoma

Research Abstract

Ryan Sullivan is a clinical and translational investigator whose main areas of interest are the development of novel molecular therapeutic agents for malignant melanoma, the translation of promising preclinical findings into early stage clinical trials, and the development of predictive biomarkers for these investigational as well as standard treatment approaches. He currently serves as the Principal Investigator (PI) of a phase I clinical trials of dabrafenib, trametinib, and navitoclax in patients with advanced melanoma open at the Dana-Farber Harvard Cancer Center (DFHCC) and sponsored by the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP), a phase II clinical trial of the combination of the BRAF inhibitor vemurafenib in combination with high-dose interleukin 2, and serve as the PI on a trial exploring the utility of a novel assay to measure BRAF in the blood.

Dr. Sullivan is board certified in Medical Oncology and an is a Assistant in Medicine and member of the Center for Melanoma and Teermer Center for Targeted Therapy at MGH, as well as a member of the Melanoma Program at DFHCC. He also is a member on the Dana-Farber/Harvard Cancer Center Institutional Review Board.